ID

39599

Description

The Effect of Anakinra on Insulin Secretion; ODM derived from: https://clinicaltrials.gov/show/NCT01285232

Link

https://clinicaltrials.gov/show/NCT01285232

Keywords

Versions (1)
  1. 2/2/20 2/2/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 2, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Glucose Intolerance NCT01285232

English

Eligibility Glucose Intolerance NCT01285232

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
impaired glucose tolerance assessed by oral glucose tolerance test and/or impaired fasting glucose ( ≥ 5.6 mmol/l) and/or hba1c levels of 5.7-6.4%
Description

Decreased glucose tolerance Oral Glucose Tolerance Test | Impaired fasting glycaemia | Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0151671
UMLS CUI [1,2]
C0029161
UMLS CUI [2]
C1272092
UMLS CUI [3]
C0474680
bmi >25 kg/m2
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
age 40-70 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known diabetes mellitus
Description

Diabetes Mellitus

Data type

boolean

Alias
UMLS CUI [1]
C0011849
fasting plasma glucose ≥ 7.0 mmol/l or hba1c ≥ 6.5%
Description

Plasma fasting glucose measurement | Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1]
C0583513
UMLS CUI [2]
C0474680
immunodeficiency or immunosuppressive treatment (including tnfα blocking agents and corticosteroids)
Description

Immunodeficiency | Immunosuppressive Agents | Tumor necrosis factor alpha blockers | Adrenal Cortex Hormones

Data type

boolean

Alias
UMLS CUI [1]
C0021051
UMLS CUI [2]
C0021081
UMLS CUI [3]
C2170827
UMLS CUI [4]
C0001617
use of anti-inflammatory drugs ( including corticosteroids and non steroidal anti-inflammatory drugs, 100 mg or less of aspirin is allowed)
Description

Anti-Inflammatory Agents | Adrenal Cortex Hormones | Anti-Inflammatory Agents, Non-Steroidal | Aspirin Dose allowed

Data type

boolean

Alias
UMLS CUI [1]
C0003209
UMLS CUI [2]
C0001617
UMLS CUI [3]
C0003211
UMLS CUI [4,1]
C0004057
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0683607
signs of current infection (fever, c-reactive protein >30 mmol/l, treatment with antibiotics, previous or current diagnosis of tuberculosis)
Description

Signs Communicable Disease | Fever | C-reactive protein measurement | Antibiotic therapy | Tuberculosis

Data type

boolean

Alias
UMLS CUI [1,1]
C0311392
UMLS CUI [1,2]
C0009450
UMLS CUI [2]
C0015967
UMLS CUI [3]
C0201657
UMLS CUI [4]
C0338237
UMLS CUI [5]
C0041296
a history of recurrent infections
Description

Recurrent infections

Data type

boolean

Alias
UMLS CUI [1]
C0239998
pregnancy or breastfeeding (contraception of at least 3 months before inclusion is required)
Description

Pregnancy | Breast Feeding | Contraceptive methods Required

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0700589
UMLS CUI [3,2]
C1514873
liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
Description

Liver disease | Aspartate aminotransferase increased | Alanine aminotransferase increased

Data type

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C0151904
UMLS CUI [3]
C0151905
renal disease defined as mdrd < 60 ml/min/1.73m2
Description

Kidney Disease MDRD

Data type

boolean

Alias
UMLS CUI [1,1]
C0022658
UMLS CUI [1,2]
C3839656
neutropenia < 2x 109/l
Description

Neutropenia

Data type

boolean

Alias
UMLS CUI [1]
C0027947
inability to understand the nature and extent of the trial and the procedures required.
Description

Study Protocol Comprehension Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C2348563
UMLS CUI [1,2]
C0162340
UMLS CUI [1,3]
C1299582
any medical condition that might interfere with the current study protocol
Description

Medical condition Interferes with Study Protocol

Data type

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C2348563
participation in a drug trial within 60 days prior to the first dose
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Back to the top of the page

Similar models

Eligibility Glucose Intolerance NCT01285232

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Decreased glucose tolerance Oral Glucose Tolerance Test | Impaired fasting glycaemia | Hemoglobin A1c measurement
Item
impaired glucose tolerance assessed by oral glucose tolerance test and/or impaired fasting glucose ( ≥ 5.6 mmol/l) and/or hba1c levels of 5.7-6.4%
boolean
C0151671 (UMLS CUI [1,1])
C0029161 (UMLS CUI [1,2])
C1272092 (UMLS CUI [2])
C0474680 (UMLS CUI [3])
Body mass index
Item
bmi >25 kg/m2
boolean
C1305855 (UMLS CUI [1])
Age
Item
age 40-70 years
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Diabetes Mellitus
Item
known diabetes mellitus
boolean
C0011849 (UMLS CUI [1])
Plasma fasting glucose measurement | Hemoglobin A1c measurement
Item
fasting plasma glucose ≥ 7.0 mmol/l or hba1c ≥ 6.5%
boolean
C0583513 (UMLS CUI [1])
C0474680 (UMLS CUI [2])
Immunodeficiency | Immunosuppressive Agents | Tumor necrosis factor alpha blockers | Adrenal Cortex Hormones
Item
immunodeficiency or immunosuppressive treatment (including tnfα blocking agents and corticosteroids)
boolean
C0021051 (UMLS CUI [1])
C0021081 (UMLS CUI [2])
C2170827 (UMLS CUI [3])
C0001617 (UMLS CUI [4])
Anti-Inflammatory Agents | Adrenal Cortex Hormones | Anti-Inflammatory Agents, Non-Steroidal | Aspirin Dose allowed
Item
use of anti-inflammatory drugs ( including corticosteroids and non steroidal anti-inflammatory drugs, 100 mg or less of aspirin is allowed)
boolean
C0003209 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0003211 (UMLS CUI [3])
C0004057 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0683607 (UMLS CUI [4,3])
Signs Communicable Disease | Fever | C-reactive protein measurement | Antibiotic therapy | Tuberculosis
Item
signs of current infection (fever, c-reactive protein >30 mmol/l, treatment with antibiotics, previous or current diagnosis of tuberculosis)
boolean
C0311392 (UMLS CUI [1,1])
C0009450 (UMLS CUI [1,2])
C0015967 (UMLS CUI [2])
C0201657 (UMLS CUI [3])
C0338237 (UMLS CUI [4])
C0041296 (UMLS CUI [5])
Recurrent infections
Item
a history of recurrent infections
boolean
C0239998 (UMLS CUI [1])
Pregnancy | Breast Feeding | Contraceptive methods Required
Item
pregnancy or breastfeeding (contraception of at least 3 months before inclusion is required)
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
Liver disease | Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range
boolean
C0023895 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0151905 (UMLS CUI [3])
Kidney Disease MDRD
Item
renal disease defined as mdrd < 60 ml/min/1.73m2
boolean
C0022658 (UMLS CUI [1,1])
C3839656 (UMLS CUI [1,2])
Neutropenia
Item
neutropenia < 2x 109/l
boolean
C0027947 (UMLS CUI [1])
Study Protocol Comprehension Unable
Item
inability to understand the nature and extent of the trial and the procedures required.
boolean
C2348563 (UMLS CUI [1,1])
C0162340 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Medical condition Interferes with Study Protocol
Item
any medical condition that might interfere with the current study protocol
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,3])
Study Subject Participation Status | Investigational New Drugs
Item
participation in a drug trial within 60 days prior to the first dose
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial